Skip to main content

Table 3 Potential therapeutic strategies and targeted drugs used in particular subtypes of triple negative breast cancer

From: Triple-negative breast cancer molecular subtyping and treatment progress

TNBC subtype Therapeutic strategies Therapeutic targeted drugs
BL1 (basal-like 1) Inhibit cell proliferation and DNA damage response Mitosis inhibitors (Paclitaxel, Docetaxel, Ixabepilone, Nab-Paclitaxel, Vinorelbine)
Cytostatics (Cisplatin, Carboplatin, Nedaplatin, Eptaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Mercaptopurine)
PARP inhibitors (Olaparib, Rucaparib, Talazoparib, Niraparib)
DNA Synthetic inhibitors (Topotecan, Irinotecan, Camptothecin, Doxorubicin, Daunorubicin, Mitomycin)
BL2 (basal-like 2) Inhibit TP63, EGFR, and MET signaling Cytostatics (Cisplatin, Carboplatin, Nedaplatin, Eptaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Mercaptopurine)
PARP inhibitors (Olaparib, Rucaparib, Talazoparib and Niraparib)
Growth Factor inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib, Olmutinib, Nazartinib, Avitinib, lapatinib, Cetuximab, Panitumumab, Vandetanib, Bevacizumab, Pertuzumab, Ramucirumab, Trastuzumab, Axitinib, Cabozantinib, Ceritinib, Crizotinib, Lenvatinib, Nilotinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib)
mTOR inhibitors (rapamycin, everolimus, RapaLink-1)
IM (immunomodulatory) Inhibit immune signaling Cytostatics (Cisplatin, Carboplatin, Nedaplatin, Eptaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Mercaptopurine)
PARP inhibitors (Olaparib, Rucaparib, Talazoparib and Niraparib)
Immune checkpoint inhibitors (Ipilimumab, Nivolumab)
M (mesenchymal) Inhibit EMT, Wnt, PI3K, mTOR, Scr, TGFβ, IGF1R, Notch Growth Factor inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib, Olmutinib, Nazartinib, Avitinib, lapatinib, Cetuximab, Panitumumab, Vandetanib, Bevacizumab, Pertuzumab, Ramucirumab, Trastuzumab, Axitinib, Cabozantinib, Ceritinib, Crizotinib, Lenvatinib, Nilotinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib)
mTOR inhibitors (Rapamycin, Everolimus, RapaLink-1)
Scr inhibitors (Bosutinib, Dasatinib)
PI3K inhibitors (Idelalisib)
MSL (mesenchymal stem-like) Inhibit EMT, Wnt, TGFβ, MAPK, Rac, PI3K, mTOR, Scr, PDGF Growth Factor inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib, Olmutinib, Nazartinib, Avitinib, lapatinib, Cetuximab, Panitumumab, Vandetanib, Bevacizumab, Pertuzumab, Ramucirumab, Trastuzumab, Axitinib, Cabozantinib, Ceritinib, Crizotinib, Lenvatinib, Nilotinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib)
mTOR inhibitors (rapamycin, everolimus, RapaLink-1)
PI3K inhibitors (Idelalisib)
MAPK inhibitors (Trametinib, Dabrafenib)
Scr inhibitors (Bosutinib, Dasatinib)
LAR (luminal androgen receptor) Inhibit AR signaling, FOXA1, and ERBB4 signaling Nonsteroidal antiandrogens (bicalutamide)
mTOR inhibitors (rapamycin, everolimus, RapaLink-1)
PI3K inhibitors (Idelalisib)